Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00235521|
Recruitment Status : Completed
First Posted : October 10, 2005
Last Update Posted : December 12, 2012
|Condition or disease||Intervention/treatment||Phase|
|Pulmonary Hypertension||Drug: aerosolized iloprost||Not Applicable|
Investigators, Study Sites: Single-center trial at the Department of Pediatric Cardiology, Department of Cardiac Surgery and Department of Anesthesiology, University Medical Center, Heidelberg, Germany Exploratory proof of concept study (Investigator initiated trial)
Indication: Postoperative pulmonary hypertension in infants and children undergoing cardiopulmonary bypass surgery for intracardiac repair of left-to-right shunt
Objectives: To compare the efficacy of aerosolized iloprost with inhaled nitric oxide to prevent postoperative pulmonary hypertensive crises
Design: Exploratory, open label, randomized study with parallel-group design;
Duration of observation: 72 hours
Population: Infants older than 4 weeks and children less than 18 months of age presenting with left-to-right shunt and increased pulmonary blood flow. Inclusion will be independent on the presence or absence of preoperative pulmonary hypertension
- 20 patients: inhaled nitric oxide (iNO) - group;
- 20 patients: aerosolized iloprost (ILO) -group
- Both groups: controlled ventilation, sedation, analgetics, inotropic substances as required, standardized intensive care treatment.
- iNO - group: concentration of iNO at 10 ppm; administered by mechanical ventilation.
- ILO - group: aerosolized Iloprost at a dose of 0,5 µg/kg body weight (12x / 24h), administered by ultrasound nebulizer.
Efficacy Parameters: Occurrence of "minor" or "major" pulmonary hypertensive crises (PHTC)
Safety Parameters: Arterial blood pressure, oxygen saturation, complete blood count
Statistical Procedures: All analyses in this exploratory trial are descriptive, giving confidence intervals for differences between treatment groups.
Primary analysis variable: Rate of occurrence of "major" or "minor" pulmonary hypertensive crises
Secondary variables: Presence of hours of pulmonary hypertension, Duration of mechanical ventilation
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Comparison of Inhaled Nitric Oxide With Aerosolized Iloprost (Ventavis®) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery|
|Study Start Date :||May 2005|
|Actual Primary Completion Date :||October 2008|
|Actual Study Completion Date :||October 2008|
- Number of pulmonary hypertensive crises (major and/or minor)
- Treatment with aerosolized ILO is equally effective as iNO in reducing the pulmonary artery pressure (PAP) within the first 72 hours after cardiopulmonary bypass surgery (CPB)
- Patients treated with aerosolized ILO can be weaned earlier from mechanical ventilation than patients on iNO treatment
- Patients treated with aerosolized ILO show the same in-hospital mortality as patients treated with iNO
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00235521
|University of Heidelberg, Medical Faculty, Department of Pediatric Cardiology|
|Heidelberg, Germany, 69120|
|Principal Investigator:||Matthias Gorenflo, MD, PhD||Heidelberg University|